On Feb. 26, 2013, the U.S. Food and Drug Administration (FDA) approved Osphena (ospemifene) to treat women with moderate to severe dyspareunia (pain during sexual intercourse), a symptom of vulvar and vaginal atrophy caused by menopause. Read more.

FDA approves Osphena for postmenopausal women with dyspareunia

FDA approves first retinal implant for adults with advanced retinitis pigmentosa

FDA approves new silicone breast implant

FDA approves Pomalyst for advanced multiple myeloma

FDA warns of potential risk of liver injury in ADPKD patients taking Samsca

FDA approves new drug treatments for type 2 diabetes

Are Accountable Care Organizations doomed to fail?

Dangers of the 12-hour shift

Television show highlights 1950s nurse midwives

New report addresses engagement with consumers

From our readers: Nurses leading from the middle

Thinking it through: The path to reflective leadership

From our readers…Value all your skills

Recognizing and stopping the destruction of vertical violence

The most expensive one percent: A case study

A new surgical intervention for reflux treatment

Soothing the sorrow of psoriasis

CDC publishes updates to immunization schedules for children and adults

Do no harm

No drugs down the drain

Teaching patients about FDA recommendations for proper medication disposal

Drugs in the environment: Nurses’ roles and responsibilities

Understanding core measures for heart-failure treatment

Perfecting your acid-base balancing act

Readers Respond

Quiz Time

When You Gotta Go Is Not Necessarily So

How long has it been going on

Revitalizing the Vagina

Building a compelling business case for nursing and quality indicators

How to achieve success in quality improvement

Nursing quality: Strength in numbers

FDA approves Botox for treatment of overactive bladder

FDA approves seasonal flu vaccine made using novel technology

FDA issue draft guidance on making opioids harder to abuse

FDA requires lower recommended doses for drugs containing zolpidem